Last reviewed · How we verify
NCT04492241
Ginkgo Leaf Extract and Armillariella Mellea Powder Oral Solution for the Treatment of Motoric Cognitive Risk Syndrome
NA trial testing Ginkgo Leaf Extract and Armillariella Mellea Powder Oral Solution in Motoric Cognitive Risk Syndrome in 800 participants. Status unknown.
31 December 2023
Quick facts
| Lead sponsor | Beijing Tiantan Hospital |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 800 |
| Start date | 5 July 2021 |
| Primary completion | 31 December 2023 |
| Estimated completion | 31 December 2024 |
| Sites | 1 location across China |
Drugs / interventions tested
- Ginkgo Leaf Extract and Armillariella Mellea Powder Oral Solution — full drug profile →
- Simulation of Ginkgo Leaf Extract and Armillariella Mellea Powder Oral Solution — full drug profile →
Conditions studied
- Motoric Cognitive Risk Syndrome — all drugs for Motoric Cognitive Risk Syndrome →
- Mild Cognitive Impairment — all drugs for Mild Cognitive Impairment →
- Aging — all drugs for Aging →
- Locomotive Syndrome — all drugs for Locomotive Syndrome →
Sponsor
Beijing Tiantan Hospital
Who can join
Adults 60 to 85, any sex, with Motoric Cognitive Risk Syndrome or Mild Cognitive Impairment. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a multi-centre, randomised, double blind, placebo controlled study on participants with Motoric Cognitive Risk Syndrome to evaluate the efficacy and safety of Ginkgo Leaf Extract and Armillariella Mellea Powder Oral Solution.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Harnessing Nature's Toolbox: Naturally Derived Bioactive Compounds in Nanotechnology Enhanced Formulations.
Sanjai C, Gaonkar SL, Hakkimane SS. · · 2024 · cited 10× · PMID 39494011 · DOI 10.1021/acsomega.4c07756
Verify or expand the search:
- PubMed search for NCT04492241
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Motoric Cognitive Risk Syndrome
Currently open trials in the same condition.
- NCT07045259 — Effect of Exergaming Program Versus Neuromuscular Exercise in Elderly People With Motor Cognitive Risk Syndrome · NA · recruiting
- NCT06451874 — Personalized Exercise Treatments for Older Veterans With Motoric Cognitive Risk Syndrome · NA · recruiting
- NCT04275817 — Cognitive Prefrail and Frailty, and Motoric Cognitive Risk Syndrome: Prevalence and Association With Incident Adverse He · active not recruiting
Other Beijing Tiantan Hospital trials
Trials by the same sponsor.
- NCT07341854 — Dexamethasone Palmitate for Postoperative Pain · NA · not yet recruiting
- NCT07527013 — Stratified Blood Pressure Management Strategy After Endovascular Treatment for Acute Ischemic Stroke · Phase 3 · not yet recruiting
- NCT07520370 — Effect of Perioperative Ulinastatin on Postoperative Stroke in Patients With Brain Tumor · NA · not yet recruiting
- NCT07526987 — Efficacy and Safety of Minocycline in Patients With Acute Ischaemic Stroke Receiving Intravenous Thrombolysis · Phase 3 · not yet recruiting
- NCT07591207 — The Efficacy and Safety of Loxoprofen Sodium Patch in Relieving Postoperative Pain After Laparoscopic Surgery · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04492241 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Beijing Tiantan Hospital
- Last refreshed: 9 December 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04492241.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing